166 related articles for article (PubMed ID: 1298870)
1. [The role of the endogenous opioid system in the pathogenesis of polycystic ovary syndrome: the altered neuroendocrine regulation of GnRH-LH is corrected after clomiphene therapy].
Barletta C; Vagiri D; Scavo D
Minerva Endocrinol; 1992; 17(3):107-19. PubMed ID: 1298870
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome.
Rebar R; Judd HL; Yen SS; Rakoff J; Vandenberg G; Naftolin F
J Clin Invest; 1976 May; 57(5):1320-9. PubMed ID: 770505
[TBL] [Abstract][Full Text] [Related]
3. Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome.
Berga SL; Yen SS
Clin Endocrinol (Oxf); 1989 Feb; 30(2):177-84. PubMed ID: 2532984
[TBL] [Abstract][Full Text] [Related]
4. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome.
Dunaif A; Mandeli J; Fluhr H; Dobrjansky A
J Clin Endocrinol Metab; 1988 Jan; 66(1):131-9. PubMed ID: 2961783
[TBL] [Abstract][Full Text] [Related]
5. Hypothalamic-pituitary-ovarian response to clomiphene citrate in women with polycystic ovary syndrome.
Kettel LM; Roseff SJ; Berga SL; Mortola JF; Yen SS
Fertil Steril; 1993 Mar; 59(3):532-8. PubMed ID: 8458453
[TBL] [Abstract][Full Text] [Related]
6. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity.
Arroyo A; Laughlin GA; Morales AJ; Yen SS
J Clin Endocrinol Metab; 1997 Nov; 82(11):3728-33. PubMed ID: 9360532
[TBL] [Abstract][Full Text] [Related]
7. Pulsatile luteinizing hormone secretion in women with polycystic ovary syndrome under clomiphene citrate. Differences between responders and nonresponders.
Sir-Petermann T; Alba F; Cohen P; Pacheco J; Devoto L; Rossmanith W
Exp Clin Endocrinol; 1990 Sep; 96(1):45-51. PubMed ID: 2126241
[TBL] [Abstract][Full Text] [Related]
8. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
[TBL] [Abstract][Full Text] [Related]
9. Effects of obesity on gonadotropin secretion in patients with polycystic ovarian disease.
Paradisi R; Venturoli S; Pasquali R; Capelli M; Porcu E; Fabbri R; Flamigni C
J Endocrinol Invest; 1986 Apr; 9(2):139-44. PubMed ID: 3086422
[TBL] [Abstract][Full Text] [Related]
10. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
Eagleson CA; Gingrich MB; Pastor CL; Arora TK; Burt CM; Evans WS; Marshall JC
J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
[TBL] [Abstract][Full Text] [Related]
11. Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian disease.
Christman GM; Randolph JF; Kelch RP; Marshall JC
J Clin Endocrinol Metab; 1991 Jun; 72(6):1278-85. PubMed ID: 1902845
[TBL] [Abstract][Full Text] [Related]
12. Endocrine changes after laparoscopic ovarian drilling in clomiphene citrate-resistant women with polycystic ovarian syndrome.
Al-Ojaimi EH
Saudi Med J; 2004 Aug; 25(8):1032-9. PubMed ID: 15322594
[TBL] [Abstract][Full Text] [Related]
13. Central opioid activity in polycystic ovary syndrome with and without dopaminergic modulation.
Barnes RB; Lobo RA
J Clin Endocrinol Metab; 1985 Oct; 61(4):779-82. PubMed ID: 3928677
[TBL] [Abstract][Full Text] [Related]
14. Steroids and neuroendocrine function in anorexia nervosa.
Casanueva FF; Borras CG; Burguera B; Muruais C; Fernández M; Devesa J
J Steroid Biochem; 1987; 27(1-3):635-40. PubMed ID: 3121928
[TBL] [Abstract][Full Text] [Related]
15. The utility of the gonadotrophin releasing hormone (GnRH) test in the diagnosis of polycystic ovary syndrome (PCOS).
Lewandowski KC; Cajdler-Łuba A; Salata I; Bieńkiewicz M; Lewiński A
Endokrynol Pol; 2011; 62(2):120-8. PubMed ID: 21528473
[TBL] [Abstract][Full Text] [Related]
16. Pituitary-ovarian relationships in polycystic ovary syndrome.
Baird DT; Corker CS; Davidson DW; Hunter WM; Michie EA; Van Look PF
J Clin Endocrinol Metab; 1977 Oct; 45(4):798-801. PubMed ID: 334789
[TBL] [Abstract][Full Text] [Related]
17. Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions.
Pagán YL; Srouji SS; Jimenez Y; Emerson A; Gill S; Hall JE
J Clin Endocrinol Metab; 2006 Apr; 91(4):1309-16. PubMed ID: 16434454
[TBL] [Abstract][Full Text] [Related]
18. The role of chronic anovulation in the polycystic ovary syndrome: normalization of sex-hormone-binding globulin levels after clomiphene-induced ovulation.
Eden JA; Place J; Carter GD; Alaghband-Zadeh J; Pawson ME
Clin Endocrinol (Oxf); 1989 Mar; 30(3):323-32. PubMed ID: 2512039
[TBL] [Abstract][Full Text] [Related]
19. Corticotropin-releasing hormone inhibition of gonadotropin release and the effect of opioid blockade.
Barbarino A; De Marinis L; Tofani A; Della Casa S; D'Amico C; Mancini A; Corsello SM; Sciuto R; Barini A
J Clin Endocrinol Metab; 1989 Mar; 68(3):523-8. PubMed ID: 2493035
[TBL] [Abstract][Full Text] [Related]
20. Use of a gonadotropin-releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome: assessment of neuroendocrine and androgen dynamics.
Hayes FJ; Taylor AE; Martin KA; Hall JE
J Clin Endocrinol Metab; 1998 Jul; 83(7):2343-9. PubMed ID: 9661606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
